WHERE TO BUY CIMAVAX EGF (LUNG CANCER VACCINE)
CimaVax is not available in the UK at the moment. It has been approved in Cuba and is currently used in the hospitals there. There are trial plans for other nations and will commence in the United States in the later parts of 2015 or in first quarter of 2016. The trials need to achieve positive results before the vaccine will become available worldwide, according to the Cancer Research UK.
The vaccine will soon be available for the Americans after President Barrack Obama suspended the restrictions on the Cuban research and medical equipment.
CimaVax-EGF is the first therapeutic vaccine produced against history lung cancer has received approval for the Cuban market. The drug took 25 years to develop by specialists at Molecular Immunology Center of Havana. The preparation is an analog of epidermal growth factor, a factor necessary for the spread and growth of cancer cells. When the drug is applied, the immune system of the body begins to attack cells which produce EGF thus reducing significantly the growth of tumor.
The drug may not be successful in preventing the disease but will improve the conditions of patients who are critically ill. Treatment using the Cimavax-EGF is recommended for patients who have gone through radiation or chemotherapy and without therapeutic alternative are considered terminal. The vaccine helps in controlling the growth of tumor without associated toxicity and will increase the quality of life and life expectancy of patients having these tumors.
The CimaVax-EGF vaccine was approved in Cuba for clinical use for persons with the 3rd and 4th stage cancer who did not encounter any positive result with chemotherapy and radiotherapy. The patients in hospitals in Cuba receive the drugs for free.
In the Caribbean island, lung cancer takes the live of up to 20,000 persons yearly. This disease is a major cause of death in 12 of the 15 provinces of Cuba.